Ed Silverman at Pharmalot says that NIH has responded to reports of NIH-funded investigators using ghostwriting firms by strengthening a conflict of interest rule, but he adds that move might not be going far enough.
Ed Silverman at Pharmalot says that NIH has responded to reports of NIH-funded investigators using ghostwriting firms by strengthening a conflict of interest rule, but he adds that move might not be going far enough.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.